학술논문
Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
Document Type
Journal
Source
Subject
Language
English
ISSN
15698041